Search results for "Staging."

showing 10 items of 715 documents

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small …

2007

Mutations of the ras gene have been reported in 20-40% of NSCLC patients. If present, they are critical for the malignant phenotype of these tumors. Therefore, targeting them by specific vaccination is a promising therapeutic approach. In a clinical trial we screened for ras mutations in patients with NSCLC. Patients with ras-positive tumors were immunized six times intradermally with a mixture of seven peptides representing the most common ras mutations. Objectives of the study were the feasibility, efficacy and safety of the vaccination. In addition, the induction of a specific immune reaction was investigated by DTH tests, and the induction of peptide-specific T cells was tested in ex vi…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesCancer VaccinesImmune systemInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineHumansLung cancerCodonAgedNeoplasm StagingImmunity Cellularbusiness.industryImmunogenicityRas PeptideVaccinationGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyMiddle Agedmedicine.diseaseCombined Modality TherapyPeptide FragmentsRecombinant ProteinsVaccinationOncologyImmunologyMutationras ProteinsFemaleImmunotherapybusinessEx vivoLung cancer (Amsterdam, Netherlands)
researchProduct

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013

Riskmedicine.medical_specialtyPalliative careColorectal cancermedicine.medical_treatmentColonoscopyAdenocarcinomaRisk AssessmentmedicineHumansNeoplasm MetastasisSigmoidoscopyWnt Signaling PathwayDigital Rectal ExaminationNeoplasm Stagingmedicine.diagnostic_testRectal Neoplasmsbusiness.industryGeneral surgeryCancerSigmoidoscopyChemoradiotherapyHematologymedicine.diseaseColorectal surgerySurgeryEuropeRadiation therapyOncologyNeoplasm Recurrence LocalbusinessColorectal SurgeryChemoradiotherapyFollow-Up StudiesAnnals of Oncology
researchProduct

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience

2014

Background: Optimally, secondary cytoreduction is acknowledged as a valid option in terms of oncologic outcome for patients with platinum-sensitive recurrent ovarian cancer. In cases of localized relapse, a laparoscopic approach has been attempted at various institutions, but studies on its role for this subset of patients still are limited. This report describes the authors' experience using laparoscopic secondary cytoreduction for patients with localized recurrent ovarian cancer. The results from a retrospective analysis of a prospective case series are reported. Methods: Between October 2011 and May 2013, 29 patients with localized recurrent ovarian cancer were selected for a laparoscopi…

Secondary cytoreductionmedicine.medical_treatmentTissue AdhesionsPostoperative ComplicationsLaparotomyLaparoscopyOvarian Neoplasmsmedicine.diagnostic_testMedicine (all)Middle Agedovarian cancerChemotherapy AdjuvantLymphatic MetastasisFemaleAdult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy; Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laparoscopy; Laparotomy; Length of Stay; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Monitoring; Intraoperative; Neoplasm Recurrence; Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Postoperative Complications; Retrospective Studies; Tissue AdhesionsAdultmedicine.medical_specialtyRecurrent ovarian cancer; Laparoscopy; Secondary cytoreductionOperative TimeAntineoplastic AgentsDisease-Free SurvivalLaparoscopicMonitoring IntraoperativeInternal medicineCarcinomamedicineHumansAgedNeoplasm StagingRetrospective StudiesLaparotomybusiness.industryGeneral surgeryCarcinomaRetrospective cohort studyLength of StayHepatologymedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIARecurrent Ovarian CancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalRecurrent ovarian cancerOvarian cancerbusinessFollow-Up StudiesAbdominal surgery
researchProduct

Anatomical distribution of sentinel lymph nodes in patients with endometrial cancer: a multicenter study.

2022

ObjectiveSentinel lymph node (SLN) mapping represents the standard approach in uterine confined endometrial cancer patients. The aim of this study was to evaluate the anatomical distribution of SLNs and the most frequent locations of nodal metastasis.MethodsThis was an observational retrospective multicenter study involving eight high volume gynecologic cancer centers in Italy. We reviewed 1576 patients with a histologically confirmed diagnosis of endometrial cancer from September 2015 to June 2020. All patients underwent total hysterectomy with salpingo-ophorectomy and SLN mapping.ResultsA total of 3105 SLNs were mapped and removed, 2809 (90.5%) of these were bilateral and 296 (9.5%) unila…

Sentinel Lymph Node BiopsyObstetrics and GynecologyHysterectomyEndometrial NeoplasmslaparoscopesSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologylaparoscopeHumansLymph Node Excisionendometrial neoplasmFemaleLymph NodesSentinel Lymph NodeNeoplasm StagingRetrospective StudiesInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in normal and pathological human oral mucosa

2011

Abstract: Cyclooxigenase (COX) is the rate-limiting enzyme for the conversion of arachidonic acid (AA) to prostaglandins (PGs). Two isoforms of COX have been identified: COX-1 is constitutively expressed in many cells and is involved in cell homeostasis, angiogenesis and cell-cell signalling; COX-2 is not expressed in normal condition however it is strongly expressed in inflammation. The oral cavity is costantly exposed to physical and chemical trauma that could lead to mucosal reactions such as hyperplasia, dysplasia and cancer. Early diagnosis is the most important issue to address for a positive outcome of oral cancer; therefore it would be useful to identify molecular markers whose expr…

Settore BIO/17 - IstologiaPathologymedicine.medical_specialtyHistologyAngiogenesiscarcinoma.Settore MED/29 - Chirurgia MaxillofaccialePathology and Forensic MedicinedysplasiaSettore MED/28 - Malattie OdontostomatologichemedicineCarcinomaHumanslcsh:QH573-671Oral mucosahuman oral mucosaNeoplasm StagingMouth neoplasmbiologyReverse Transcriptase Polymerase Chain Reactionlcsh:CytologyMouth MucosahyperplasiaCancerGeneral MedicineHyperplasiamedicine.diseaseImmunohistochemistryGene Expression Regulation Neoplasticmedicine.anatomical_structurecyclooxigenasesCyclooxygenase 2DysplasiaCyclooxygenase 1biology.proteinMouth NeoplasmsCyclooxygenasecyclooxigenases human oral mucosa hyperplasia dysplasia carcinomaPrecancerous Conditions
researchProduct

Instagram tra realismo e messinscena

2018

L'articolo esplora l'idea che le pratiche post-fotografiche legate ad instagram occupano uno spazio intermedio tra quello dell'occhio meccanico (che nell'era fotografica tendeva a rappresentare oggettivamente la realtà) e quello della messa in scena del sé nel quale gli hashtag costituiscono i mezzi fondamentali attraverso i quali promuovere la propria immagine sul palcoscenico dei social media. The article explores the idea that post-photographic practices related to instagram occupy an intermediate space between that of the mechanical eye (which in the photographic era tended to objectively represent reality) and that of the staging of the self in which hashtags are the fundamental means …

Settore L-ART/06 - Cinema Fotografia E Televisioneinstagram photography staging realityinstagram fotografia messinscena realtà
researchProduct

Effectiveness of clinical and instrumental follow-up for cutaneous melanoma

2022

Introduction: Follow-up guidelines for melanoma greatly differ in the methods of screening for recurrence, and timing and duration of the follow up, with many areas of controversy and a lack of general consensus. The aims of this study are to present our protocol and case series for follow up and to summarize and discuss current literature on melanoma follow-up guidelines/recommendations in different countries. Methods: We retrospectively reviewed 539 patients operated for melanoma between 2004 and 2013 at the same Institution. Data on the diagnostic role of the different clinical and instrumental detection methods were adjusted for sex, age at diagnosis, staging and evaluated by Fisher's e…

Skin NeoplasmsOncologyRecurrenceHumansSurgeryFollow-up Local recurrences Melanoma Metastases Prognosis Surgical oncologyNeoplasm Recurrence LocalMelanomaFollow-Up StudiesNeoplasm StagingRetrospective StudiesSurgical Oncology
researchProduct

Increased frequencies of CD11b+CD33+CD14+HLA-DRlowmyeloid-derived suppressor cells are an early event in melanoma patients

2014

Myeloid-derived suppressor cells (MDSC) are a heterogeneous cell population characterized by immunosuppressive activity. Elevated levels of MDSC in peripheral blood are found in inflammatory diseases as well as in malignant tumors where they are supposed to be major contributors to mechanisms of tumor-associated tolerance. We investigated the frequency and function of MDSC in peripheral blood of melanoma patients and observed an accumulation of CD11b(+) CD33(+) CD14(+) HLA-DR(low) MDSC in all stages of disease (I-IV), including early stage I patients. Disease progression and enhanced tumor burden did not result in a further increase in frequencies or change in phenotype of MDSC. By investig…

Skin Neoplasmsmedicine.medical_treatmentCD14Sialic Acid Binding Ig-like Lectin 3CD33PopulationLipopolysaccharide ReceptorsReceptors Antigen T-CellDermatologyBiologyLymphocyte ActivationT-Lymphocytes RegulatoryBiochemistryImmune toleranceTetanus ToxoidHLA-DRmedicineHumansMyeloid CellsLymphocyte CounteducationMelanomaMolecular BiologyCells CulturedCell ProliferationNeoplasm Stagingeducation.field_of_studyCD11b AntigenMelanomaInterleukin-8HLA-DR AntigensImmunotherapymedicine.diseaseCoculture TechniquesTumor BurdenCase-Control StudiesImmunologyDisease ProgressionLeukocytes MononuclearMyeloid-derived Suppressor CellTumor EscapeExperimental Dermatology
researchProduct

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1

2016

International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.

SorafenibCancer Researchmedicine.medical_specialtysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHCC; immunotherapy; liver cancer; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHepatocellularGeneral MedicineHepatologymedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisLiver cancerbusinessmedicine.drugFuture Oncology
researchProduct

Sorafenib in advanced hepatocellular carcinoma

2008

none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Seconda…

SorafenibMaleNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesPlaceboGastroenterologyDouble-Blind MethodInternal medicinemedicineCarcinomaHumansHEPATOCELLULAR CARCINOMAProtein Kinase InhibitorsAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryPhenylurea CompoundsHazard ratioBenzenesulfonatesLiver NeoplasmsGeneral MedicineTREATMENTMiddle AgedSorafenibmedicine.diseaseInterim analysisSurvival AnalysisRecurrent Hepatocellular Carcinomadigestive system diseasesSurgeryHEPATOCELLULAR CARCINOMA; SORAFENIB; TREATMENTChemotherapy AdjuvantHepatocellular carcinomaDisease ProgressionFemaleraf KinasesbusinessLiver cancermedicine.drug
researchProduct